El-Battrawy I, Roterberg G, Liebe V, et al. - Data were presented and analyzed following a systematic review of literature compiled from a thorough database search by the experts in order to explain the data assimilated in a total of 11 studies, analyzing the outcome in 747 patients with Brugada syndrome (BrS, correlated with sudden cardiac death [SCD]) receiving implantable cardioverter-defibrillator (ICD). About 15.3% and 10.4% of the patients were admitted because of SCD and suffered from atrial arrhythmia, respectively. In 18.1% of the patients, appropriate shocks were recorded over a mean follow-up period of 82.3 months. Lead failure and fracture, lead perforation, lead dislodgement, infection, pain, subclavian vein thrombosis, pericardial effusion, endocarditis, psychiatric problems, and pneumothorax were the complications that were listed. In 18.1% of the patients, inappropriate shocks were recorded. The management of inappropriate shocks was accomplished by pulmonary vein isolation, drug treatment with sotalol or sotalol with beta-blocker, and hydroquinidine. Thus, in BrS, ICD therapy was concluded to be related to appropriate ICD-related complications including a substantial risk of inappropriate shocks more often in symptomatic BrS patients.